Complement activation in wasp venom-induced acute kidney injury
In this study, a complement-depleted mouse model was used to investigate the role of complement in wasp venom-induced AKI. Mice were randomly categorized into control, cobra venom factor (CVF), AKI, and CVF + AKI groups. Compared to the AKI group, the CVF + AKI group showed improved pathological changes in kidneys and reduced blood urea nitrogen (BUN) levels. The expression levels of renal complement 3 (C3), complement 5 (C5), complement 1q (C1q), factor B (FB), mannose-binding lectin (MBL), and C5b-9 in AKI group were upregulated compared with the control group. Conversely, the renal tissue expression levels of C3, C5, C1...
Source: Renal Failure - April 21, 2024 Category: Urology & Nephrology Authors: Rui Cheng Liang Xu Jianhua Gong Fanglin Yu Ying Lv Hai Yuan Fengqi Hu Source Type: research
Rhabdomyolysis due to Acute Alcohol Intoxication
A 27-year-old male was admitted with pain, swelling and weakness of bilateral lower limbs since 5 days associated with passage of high coloured urine and decreased urine output. He reported alcohol binge of country-made Indian whiskey (around 600 ml) a day prior to onset of symptoms. There was no history of trauma, drug intake or any form of physical exertion before onset of symptoms. He was managed at a local hospital with intravenous fluids before presentation to our institute. Physical examination showed stable vitals with bilateral lower limb tenderness, pitting edema up to calf region and restriction of movements in b...
Source: The American Journal of Medicine - April 20, 2024 Category: General Medicine Authors: Dr Vishali Chandrasekhar, Dr Harpreet Singh, Dr Aravind Subramanian, Dr Deba Prasad Dhibhar, Dr Vikas Suri, Dr Ashish Bhalla Tags: Clinical Communication to the Editor Source Type: research
Uncontrollable Movements: A Case of Rhabdomyolysis Secondary to Opioid-Resistant Vaso-occlusive Pain
1. Recall that frequent reassessment of pain and clinical status is vital for patients with severe VOE in order to differentiate between inadequate opioid dosing and opioid hyperalgesia.2. Consider evaluation for rhabdomyolysis in patients with VOE and uncontrolled pain. (Source: Journal of Pain and Symptom Management)
Source: Journal of Pain and Symptom Management - April 19, 2024 Category: Palliative Care Authors: Emily N. Kelly, Kavitha Norton, Kyle Quirk, Sarah E. Ehrman Source Type: research
Naja nigricincta nigricincta venom, a murine model. Evaluation of skeletal and cardio-myonecrosis, kidney injury and inflammatory response along with neutralisation efficacy by the SAIMR/SAVP - and EchiTAb-Plus-ICP polyvalent antivenoms
Toxicon. 2024 Apr 15:107719. doi: 10.1016/j.toxicon.2024.107719. Online ahead of print.ABSTRACTAfrican spitting cobra, Naja nigricincta nigricincta (Zebra snake), envenomation is an important cause of snakebite morbidity and mortality in Namibia. The snake is endemic to central and northern Namibia as well as southern Angola. The venom is mainly cytotoxic, resulting in aggressive dermo-necrosis and often accompanied by severe systemic complications. No specific antivenom exists. Rhabdomyolysis, systemic inflammatory response, haemostatic abnormalities, infective necrotising fasciitis as well as acute kidney failure have be...
Source: Toxicon - April 17, 2024 Category: Toxicology Authors: Esta L Saaiman Engelbrecht Vinny Naidoo Christo J Botha Source Type: research
Decompression sickness followed by diabetic ketoacidosis and sepsis shock: an unusual case report
Undersea Hyperb Med. 2024 First Quarter;51(1):41-46.ABSTRACTDecompression sickness (DCS) is caused by abrupt changes in extracorporeal pressure with varying severity. Symptoms range from mild musculoskeletal pain to severe organ dysfunction and death, especially among patients with chronic underlying disease. Here, we report an unusual case of a 49-year-old man who experienced DCS after a dive to a depth of 38 meters. The patient's symptoms progressed, starting with mild physical discomfort that progressed to disturbance of consciousness on the second morning. During hospitalization, we identified that in addition to DCS, ...
Source: Undersea and Hyperbaric Medicine - April 14, 2024 Category: Sports Medicine Authors: Anwei Liu Xiaogan Hou Jing Nie Qiang Wen Zhiguo Pan Source Type: research
Decompression sickness followed by diabetic ketoacidosis and sepsis shock: an unusual case report
Undersea Hyperb Med. 2024 First Quarter;51(1):41-46.ABSTRACTDecompression sickness (DCS) is caused by abrupt changes in extracorporeal pressure with varying severity. Symptoms range from mild musculoskeletal pain to severe organ dysfunction and death, especially among patients with chronic underlying disease. Here, we report an unusual case of a 49-year-old man who experienced DCS after a dive to a depth of 38 meters. The patient's symptoms progressed, starting with mild physical discomfort that progressed to disturbance of consciousness on the second morning. During hospitalization, we identified that in addition to DCS, ...
Source: Undersea and Hyperbaric Medicine - April 14, 2024 Category: Sports Medicine Authors: Anwei Liu Xiaogan Hou Jing Nie Qiang Wen Zhiguo Pan Source Type: research
Decompression sickness followed by diabetic ketoacidosis and sepsis shock: an unusual case report
Undersea Hyperb Med. 2024 First Quarter;51(1):41-46.ABSTRACTDecompression sickness (DCS) is caused by abrupt changes in extracorporeal pressure with varying severity. Symptoms range from mild musculoskeletal pain to severe organ dysfunction and death, especially among patients with chronic underlying disease. Here, we report an unusual case of a 49-year-old man who experienced DCS after a dive to a depth of 38 meters. The patient's symptoms progressed, starting with mild physical discomfort that progressed to disturbance of consciousness on the second morning. During hospitalization, we identified that in addition to DCS, ...
Source: Undersea and Hyperbaric Medicine - April 14, 2024 Category: Sports Medicine Authors: Anwei Liu Xiaogan Hou Jing Nie Qiang Wen Zhiguo Pan Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling
AAPS PharmSciTech. 2024 Apr 11;25(4):86. doi: 10.1208/s12249-024-02803-z.ABSTRACTThe common disorders irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) can modify the drugs' pharmacokinetics via their induced pathophysiological changes. This work aimed to investigate the impact of these two diseases on pravastatin oral bioavailability. Rat models for IBS and IBD were used to experimentally test the effects of IBS and IBD on pravastatin pharmacokinetics. Then, the observations made in rats were extrapolated to humans using a mechanistic whole-body physiologically-based pharmacokinetic (wbPBPK) model. The r...
Source: AAPS PharmSciTech - April 11, 2024 Category: Drugs & Pharmacology Authors: Motasem M Alsmadi Alla A Abudaqqa Nasir Idkaidek Nidal A Qinna Ahmad Al-Ghazawi Source Type: research
Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
Clin Pharmacol Ther. 2024 Apr 8. doi: 10.1002/cpt.3258. Online ahead of print.ABSTRACTTranslational approaches can benefit post-marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug-drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with ...
Source: Clinical Pharmacology and Therapeutics - April 9, 2024 Category: Drugs & Pharmacology Authors: Elpida Kontsioti Simon Maskell Isobel Anderson Munir Pirmohamed Source Type: research
Identifying Drug-Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
Clin Pharmacol Ther. 2024 Apr 8. doi: 10.1002/cpt.3258. Online ahead of print.ABSTRACTTranslational approaches can benefit post-marketing drug safety surveillance through the growing availability of systems pharmacology data. Here, we propose a novel Bayesian framework for identifying drug-drug interaction (DDI) signals and differentiating between individual drug and drug combination signals. This framework is coupled with a systems pharmacology approach for automated biological plausibility assessment. Integrating statistical and biological evidence, our method achieves a 16.5% improvement (AUC: from 0.620 to 0.722) with ...
Source: Clinical Pharmacology and Therapeutics - April 9, 2024 Category: Drugs & Pharmacology Authors: Elpida Kontsioti Simon Maskell Isobel Anderson Munir Pirmohamed Source Type: research
